Retigabine
Retigabine structure
|
Common Name | Retigabine | ||
|---|---|---|---|---|
| CAS Number | 150812-12-7 | Molecular Weight | 303.331 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 430.0±45.0 °C at 760 mmHg | |
| Molecular Formula | C16H18FN3O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 213.9±28.7 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Enhanced in vitro CA1 network activity in a sodium channel β1(C121W) subunit model of genetic epilepsy.
Epilepsia 55(4) , 601-8, (2014) A NaV β1(C121W) mouse model of human genetic epilepsy has enhanced neuronal excitability and temperature sensitivity attributed to a decreased threshold for action potential firing in the axon initial segment. To investigate the network consequences of this n... |
|
|
Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel.
Expert Opin. Drug Saf. 12(6) , 847-55, (2013) Complex-partial seizures are frequently resistant to antiepileptic therapy. Two new medications with mechanisms of action novel within the antiepileptic class have recently received approval for the adjunctive treatment of partial (focal) seizures.A Medline s... |
|
|
Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review.
Clin. Ther. 34(9) , 1845-56.e1, (2012) Ezogabine, also known as retigabine, is a recently approved anticonvulsant medication with a novel mechanism of action. It activates low-threshold voltage-gated potassium channels, leading to hyperpolarization of the membrane potential, stabilization of the r... |
|
|
[Retigabine - a new antiepileptic drug with a different mechanism of action].
Postepy. Hig. Med. Dosw. 67 , 973-81, (2013) Retigabine belongs to a new generation of antiepileptic drugs. Its mechanism of action is different from that previously known. Retigabine opens potassium channels of subfamily Kv 7, especially Kv 7.2 and Kv 7.3. The drug enhances GABA-ergic transmission. It ... |
|
|
P-retigabine: an N-propargyled retigabine with improved brain distribution and enhanced antiepileptic activity.
Mol. Pharmacol. 87(1) , 31-8, (2015) Retigabine (RTG, [ethyl N-[2-amino-4-[(4-fluorophenyl)methyl]amino] phenyl] carbamate]) is a first-in-class antiepileptic drug that acts by potentiating neuronal KCNQ potassium channels; however, it has less than optimal brain distribution. In this study, we ... |
|
|
[Retigabine. A novel anticonvulsant drug for the adjunctive treatment of partial seizures].
Med. Monatsschr. Pharm. 35(5) , 166-71, (2012)
|
|
|
Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.
Pharmacoeconomics 31(2) , 101-10, (2013) The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of retigabine (GlaxoSmithKline) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of adults with partial-onset seizures in epilep... |
|
|
Retigabine: chemical synthesis to clinical application.
CNS Drug Rev. 11(1) , 1-20, (2005) Retigabine [D23129; N-(2-amino-4-(4-fluorobenzylamino)-phenyl)carbamic acid ethyl ester] is an antiepileptic drug with a recently described novel mechanism of action that involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) chann... |
|
|
Ezogabine (retigabine).
Nat. Rev. Drug Discov. 10(10) , 729-30, (2011) Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the U.S. Food and Drug Administration (F.D.A.) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was gr... |
|
|
The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Epilepsia 53(3) , 412-24, (2012) The pharmacologic profile of retigabine [RTG (international nonproprietary name); ezogabine, EZG (U.S. adopted name)], is different from all currently approved antiepileptic drugs (AEDs). Its primary mechanism of action (MoA) as a positive allosteric modulato... |